Oncologic Safety of Fat Grafting for Autologous Breast Reconstruction in an Animal Model of Residual Breast Cancer
- 27 December 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Plastic and Reconstructive Surgery
- Vol. 143 (1), 103-112
- https://doi.org/10.1097/prs.0000000000005085
Abstract
Clinical outcomes suggest that postoncologic reconstruction with fat grafting yields cumulative incidence curves of recurrence comparable to those of other breast reconstruction procedures; however, results from experimental research studies suggest that adipose stem cells can stimulate cancer growth. In this study, a novel animal model of residual cancer was developed in mouse mammary pads to test whether lipofilling impacts the probability of locoregional recurrence of breast cancer after breast conserving surgery. Mammary fat pads of female NOD-SCID gamma mice were each injected with MCF-7 cells in Matrigel. Tumors were allowed to engraft for 2 weeks, after which time either sterile saline (n = 20) or human fat graft (n = 20) was injected adjacent to tumor sites. After 8 weeks, tumors were assessed for volume measurement, histologic grade, Ki67 positivity, and metastatic spread. Animals receiving lipofilling after tumor cell engraftment had lower tumor volume and mass (p = 0.046 and p = 0.038, respectively). Macroscopic invasion was higher in the saline group. Histologic grade was not significantly different in the two groups (p = 0.17). Ki67 proliferation index was lower in tumors surrounded by fat graft (p = 0.01). No metastatic lesion was identified in any animal. Adipose transfer for breast reconstruction performed in the setting of residual breast tumor in a clinically relevant animal model did not increase tumor size, proliferation, histologic grade, or metastatic spread. This study supports the oncologic safety of lipofilling as part of the surgical platform for breast reconstruction after cancer therapy.Keywords
This publication has 45 references indexed in Scilit:
- Mesenchymal Stem Cell 1 (MSC1)-Based Therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and MetastasisPLOS ONE, 2012
- Interleukin-8 derived from local tissue-resident stromal cells promotes tumor cell invasionMolecular Carcinogenesis, 2011
- Choosing the right cell line for breast cancer researchBreast Cancer Research, 2011
- Locoregional recurrence risk after lipofilling in breast cancer patientsAnnals of Oncology, 2011
- Cancer-Associated Adipocytes Exhibit an Activated Phenotype and Contribute to Breast Cancer InvasionCancer Research, 2011
- Regenerative Therapy and Cancer: In Vitro and In Vivo Studies of the Interaction Between Adipose-Derived Stem Cells and Breast Cancer Cells from Clinical IsolatesTissue Engineering, Part A, 2011
- Breast Cancer Subtypes and the Risk of Local and Regional RelapseJournal of Clinical Oncology, 2010
- Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cellsOncogene, 2009
- Micro-Environmental Mechanical Stress Controls Tumor Spheroid Size and Morphology by Suppressing Proliferation and Inducing Apoptosis in Cancer CellsPLOS ONE, 2009
- Mesenchymal Stem Cells Derived from Human Adipose Tissues Favor Tumor Cell Growth in vivoStem Cells and Development, 2008